Nektar Therapeutics (NASDAQ:NKTR)‘s stock had its “buy” rating reiterated by analysts at William Blair in a research note issued to investors on Tuesday, TipRanks reports. Other research analysts also recently issued reports about the company. Mizuho reissued a “buy” rating on shares of Nektar Therapeutics in a research note on Tuesday, February 19th. Piper Jaffray […]
